Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of DME

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.

YOSEMITE and RHINE: 2-year results of faricimab in diabetic macular edema indicate reduced treatment burden

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

THR-687 protective against diabetic macular edema hallmarks in diabetic rats

THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.

Unity provides Phase 1 study data for UBX1325

February 14, 2022

During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

KALAHARI Study shows THR-149 is safe, well-tolerated for DME

February 12, 2022

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.